ONCIMMUNE HOLDINGS PLC

Pre-Annual General Meeting Information • Feb 3, 2025

National Storage Mechanism | Additional information

RNS Number : 3591V

Oncimmune Holdings PLC

03 February 2025

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Notice of Annual General Meeting

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry enabling precision medicine, today announces that the Notice of Annual General Meeting ("AGM") has been sent to shareholders.

The AGM will be held on 27 February 2025 at 10:30 a.m. at 201 Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT.

The Notice of AGM has been sent to shareholders and can also be viewed on the "Investors" section of the Company's website at www.oncimmune.com .

The audit process for the Company's financial results for the 12 months ended 31 August 2024 ("FY2024") is continuing in the ordinary course and the Company expects its annual report, including the financial statements for FY2024, to be published by the end of February 2025 and for this to be laid before a separate general meeting.

For further information:

contact@oncimmune.com

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash, Callum Davidson, Trisyia Jamaludin (Corporate Finance)

Nigel Birks (Life Science Specialist Sales)

Ondraya Swanson (ECM)

+44 (0) 20 7220 0500

Zeus (Joint Broker)

Dominic King, Dan Bate

+44 (0)20 3829 5000

About Oncimmune

Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

For more information, visit  www.oncimmune.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAURSBRVVUAOAR